LIXTE Biotechnology and Netherlands Cancer Institute Dose First Patient in Roche-Supported Trial for Metastatic Colorectal Cancer

LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer In...

August 27, 2024 | Tuesday | News
Curebound Announces Major Milestones for Cancer Research Grants, Secures Over $5.3M in Follow-On Funding

-Curebound, a philanthropic organization that raises and invests strategic funding for cancer research, is announcing important updates on its grant reci...

August 22, 2024 | Thursday | News
FDA Accepts Application for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy(ipilimumab) compared to in...

August 22, 2024 | Thursday | News
BioSenic Secures Key Japanese Patent for Enhanced Arsenic-Based Therapeutics in Autoimmune and Cancer Treatments

Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...

August 14, 2024 | Wednesday | News
Shanghai Junshi Biosciences’ Toripalimab sNDA Accepted by NMPA for First-Line Treatment of Advanced Melanoma

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

August 13, 2024 | Tuesday | News
Angiex Initiates Phase 1 Trial of Innovative AGX101 Cancer Therapy with Abzena's Support

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
WestGene Biopharma Achieves Historic Dual IND Approvals for World's First mRNA Vaccine Targeting EBV-Related Cancers

WestGene Biopharma is proud to announce that its innovative mRNA therapeutic cancer vaccine, WGc-043, has received dual Investigational New Drug (IND) ap...

August 09, 2024 | Friday | News
Angiex Initiates Phase 1 Clinical Trial for AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Tumors

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

    NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria...

August 08, 2024 | Thursday | News
Thermo Fisher Scientific's SeCore™ CDx HLA A Sequencing System Receives FDA Clearance as Companion Diagnostic for Adaptimmune’s TECELRA® TCR Therapy

Thermo Fisher Scientific Inc., the world leader in serving science,  announced that its SeCore™ CDx HLA A Sequencing System has been granted 5...

August 07, 2024 | Wednesday | News
Illumina Expands Oncology Testing with High-Throughput Assays for NovaSeq X Series

llumina a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeq™ X Series custo...

August 06, 2024 | Tuesday | News
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy

Agilent that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovia...

August 05, 2024 | Monday | News
FDA Grants Accelerated Approval for TECELRA in Advanced Synovial Sarcoma Treatment

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment ...

August 02, 2024 | Friday | News
Bio-Rad Laboratories Announces Study on Rapid Bispecific Antibody Generation

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the publication of a peer-reviewed stud...

August 01, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close